We Update you with the Clock Running. Health Care News, Disease, Diagnose, Physicians, Residents, Medical Officers, Nursing Care, Technical Staff, Health Policies, Organizations, Certification, Standards, Alerts, and All about Worlds Health. Step to Facilitate the Health Care Professionals and Patients. Provide Safety and Quality to Patient's, Health Care staff, Explains Patient Family Education and Rights.
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects Triolex (He3286) As A Oral Anti-Inflammatory Drug Candidate
Cystic Fibrosis Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced that Cystic Fibrosis Foundation Therapeutics, Inc, (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, has selected Hollis-Eden's TRIOLEX? (HE3286) as a drug candidate for lung inflammation associated with cystic fibrosis (CF) under their existing collaboration agreement.
